Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer

被引：0
|
作者：
Toffart, A. -C. [1 ,2 ]
Sakhri, L. [1 ,2 ]
Moro-Sibilot, D. [1 ,2 ]
机构：
[1] Ctr Hosp Univ A Michallon, UM Oncol Thorac, F-38043 Grenoble 9, France
[2] Univ Grenoble 1, Inst A Bonniot, INSERM, U823, Grenoble, France
来源：
REVUE DE PNEUMOLOGIE CLINIQUE | 2013年 / 69卷 / 02期
关键词：
EML4-ALK; Lung cancer; Crizotinib; Targeted therapy; Never smoker; Adenocarcinoma; EML4-ALK FUSION GENE; KINASE INHIBITOR; RESISTANCE; REARRANGEMENT; MUTATIONS; EFFICACY; MET; NPM;
D O I：
10.1016/j.pneumo.2012.11.010
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Crizotinib is a small orally-administered ALK inhibitor for patients with non-small cell lung cancer with EML4-ALK rearrangement (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase). This fusion gene is detected with a break apart fluorescence in situ hybridization (FISH) assay. Phase I to III trials have shown an interesting disease control rate and acceptable tolerability. Crizotinib is available in France under temporary use authorization. New potentially effective therapeutics in ALK-positive NSCLC are being developed. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：111 / 116
页数：6
相关论文
共 50 条
  • [31] Treatment of brain metastases in ALK-positive non-small cell lung cancer
    Ceddia, Serena
    Codacci-Pisanelli, Giovanni
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 165
  • [32] How I treat ALK-positive non-small cell lung cancer
    McCusker, Michael G.
    Russo, Alessandro
    Scilla, Katherine A.
    Mehra, Ranee
    Rolfo, Christian
    ESMO OPEN, 2019, 4
  • [33] Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer
    Yoshida, Tatsuya
    Oya, Yuko
    Tanaka, Kosuke
    Shimizu, Junichi
    Horio, Yoshitsugu
    Kuroda, Hiroaki
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    LUNG CANCER, 2016, 97 : 43 - 47
  • [34] Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
    Mogenet, Alice
    Tomasini, Pascale
    Greillier, Laurent
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S383 - S386
  • [35] Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    Shaw, A. T.
    Varghese, A. M.
    Solomon, B. J.
    Costa, D. B.
    Novello, S.
    Mino-Kenudson, M.
    Awad, M. M.
    Engelman, J. A.
    Riely, G. J.
    Monica, V.
    Yeap, B. Y.
    Scagliotti, G. V.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 59 - 66
  • [36] Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer
    Wilner, Keith D.
    Usari, Tiziana
    Polli, Anna
    Kim, Elizabeth E.
    FUTURE ONCOLOGY, 2019, 15 (10) : 1097 - 1103
  • [37] From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
    Pirker, Robert
    Filipits, Martin
    ESMO OPEN, 2019, 4 (05)
  • [38] Targeted Therapy for Non-Small Cell Lung Cancer
    Jett, James R.
    Carr, Laurie L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 188 (08) : 907 - 912
  • [39] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Nakagawa, Kazuhiko
    Seto, Takashi
    Crino, Lucio
    Ahn, Myung-Ju
    De Pas, Tommaso
    Besse, Benjamin
    Solomon, Benjamin J.
    Blackhall, Fiona
    Wu, Yi-Long
    Thomas, Michael
    O'Byrne, Kenneth J.
    Moro-Sibilot, Denis
    Camidge, D. Ross
    Mok, Tony
    Hirsh, Vera
    Riely, Gregory J.
    Iyer, Shrividya
    Tassell, Vanessa
    Polli, Anna
    Wilner, Keith D.
    Jaenne, Pasi A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25) : 2385 - 2394
  • [40] Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report
    Zhu, Zhouyu
    Chai, Ying
    MEDICINE, 2017, 96 (45)
12345